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Summary
Background Indications for chemotherapy in gestational trophoblastic disease include raised human chorionic 
gonadotropin (hCG) concentrations 6 months after uterine evacuation of hydatidiform mole, even when values are 
falling. We aimed to establish whether chemotherapy is always necessary in these patients.
Methods We retrospectively identiﬁ ed women registered between January, 1993, and May, 2008, at Charing Cross 
Hospital, London, UK, who had persistently high hCG concentrations 6 months after evacuation of hydatidiform 
mole. Rates of hCG normalisation, relapse, and death were assessed in patients continued under surveillance and 
those who received chemotherapy after 6 months. We postulated that a surveillance policy would be clinically 
acceptable if hCG values returned to normal in 75% of patients or more.
Findings 76 (<1%) of 13 960 patients with hydatidiform moles had persistently high hCG concentrations of more than 
5 IU/L 6 months after evacuation. 66 (87%) patients continued under surveillance and hCG values spontaneously 
returned to normal without chemotherapy in 65 (98%) of these patients. Values in one patient did not become normal 
because of chronic renal failure, but she remains healthy. Ten patients received chemotherapy, and hCG concentrations 
returned to normal in eight (80%) of these individuals (surveillance vs chemotherapy groups p=0·044) and remained 
slightly high (6–11 IU/L) in two without any associated clinical problems oﬀ  treatment. We noted no signiﬁ cant 
diﬀ erences between individuals in the surveillance and chemotherapy groups, apart from lower median hCG 
concentrations 6 months after evacuation in those under surveillance than in those given chemotherapy (13 IU/L, 
range 5–887, vs 157 IU/L, range 6–6438; p=0·004). Overall, there were no deaths in this series.
Interpretation A surveillance policy seems to be clinically acceptable in patients with low and declining concen trations 
of hCG 6 months after evacuation of hydatidiform mole.
Funding National Commissioning Group, Imperial Experimental Cancer Medicine Centre, Imperial Biomedical 
Research Centre, and Cancer Research UK.
Introduction
Genetically, partial and complete hydatidiform moles 
overexpress paternal genes. Complete moles are diploid 
and androgenetic in origin,1,2 whereas partial moles are 
triploid and have one maternal set and two paternal sets 
of chromosomes.3,4 Hydatidiform moles occur more 
frequently in east Asia than in most western populations, 
in which the incidence seems to be fairly uniform.5 In the 
UK, about one to three per 1000 pregnancies are either 
complete or partial moles.6 Hydatidiform moles can aﬀ ect 
women of any reproductive age, but relative risks are 
higher in those younger than 16 years or older than 
45 years than in other age groups.7,8
Most women with molar pregnancy present with 
vaginal bleeding in the ﬁ rst trimester and all have a raised 
serum or urine human chorionic gonadotropin (hCG) 
concentration (5 IU/L or more in serum on the Charing 
Cross hCG assay). Subsequent pelvic ultrasonography 
might show a failing normal, abnormal, or possible 
molar pregnancy, but cannot enable diagnosis of 
hydatidiform mole, so a dilatation and curettage is 
necessary.9 This procedure allows histological examination 
of the products of conception and an appropriate 
diagnosis can be made.10
Residual tissue spontaneously regresses in most 
patients, with a corresponding normalisation of hCG 
concentrations in about 92% of patients.6 However, 
malignant transformation to gestational trophoblastic 
neoplasia after complete hydatidiform mole occurs in 
roughly 15% of cases and after partial hydatidiform moles 
in 0·5–1%.11–13 This malignant transformation requires 
prompt recognition so that lifesaving chemotherapy can 
be instituted. About 8% of UK patients with hydatidiform 
moles undergo chemotherapy, usually as single drug 
treatment with methotrexate or dactinomycin.6
To ensure rapid detection of post-mole gestational 
trophoblastic neoplasia, all patients with hydatidiform 
moles in the UK are registered with one of three 
centralised hCG monitoring and surveillance pro-
grammes (Ninewells Hospital, Dundee; Weston Park 
Hospital, Sheﬃ  eld; and Charing Cross Hospital, London).9 
The most common reason for diagnosis of post-mole 
gestational trophoblastic neoplasia is a plateau or rise in 
hCG values. Another internationally agreed reason for 
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diagnosis of gestational trophoblastic neoplasia and 
initiation of chemotherapy is a persistently raised hCG 
concentration at 6 months, even if the value is falling 
(panel 1).6,14,15 This criterion is used because increasing 
tumour age is thought to entail a worse prognosis or high 
risk of resistance to single agent chemotherapy, or both, 
presumably because of further acquired genetic mutations 
with time.16 Increased time intervals between antecedent 
pregnancy and start of chemotherapy are associated with 
higher mortality rates.16–19 
However, evidence from twin and singleton molar-
pregnancy studies20,21 showing no increased frequency of 
gestational trophoblastic neoplasia or disease resistant to 
single-agent therapy in moles that were evacuated late as 
opposed to early in pregnancy suggests that the malignant 
potential of moles is established very early in the ﬁ rst 
trimester. Moreover, other data suggest that such acquired 
adverse mutations probably occur much later than 
6 months after evacuation in the natural course of the 
disease. Thus, the crucial time for an adverse outcome for 
most patients with gestational trophoblastic neoplasia 
seems to be 2·8 years from time of causal pregnancy,17 or 
for placental site trophoblastic tumour after 4 years.18 
Additionally, chemotherapy given at or after 6 months 
subsequent to evacuation was eﬀ ective in 28 women,22 
suggesting that, if surveillance were undertaken and 
failed, eﬀ ective salvage treatment could still be given. 
Collectively, these clinical results indicate that 
chemotherapy might not be necessary in women who 
have an increased but falling hCG concentration 6 months 
after uterine evacuation of a hydatidiform mole.
Here, we postulate that a policy of continued surveil-
lance after 6 months would be clinically acceptable if 
hCG concentrations spontaneously returned to normal 
in more than 75% of patients within 12 months of 
evacuation, with less than 25% developing gestational 
trophoblastic neoplasia and requiring chemotherapy. 
Therefore, we retrospectively analysed the outcome of 
patients with persistently raised but falling hCG 
concentrations 6 months after evacuation of hydatidi-
form moles.
Methods
Patients and study design
We retrospectively identiﬁ ed patients with persistently 
raised concentrations of serum hCG at 6 months after 
evacuation of molar pregnancy between January, 1993, 
and May, 2008, from the electronic database of gestational 
trophoblastic disease at Charing Cross Hospital. At this 
hospital, hCG detection and monitoring is done with a 
non-commercial, one-site, in-house, competitive hCG 
radioimmunoassay that uses a rabbit polyclonal antibody. 
Serum hCG concentrations of less than 5 IU/L are classed 
as normal (in urine, less than 25 IU/L).23 Once registered, 
women with molar preg nancies have serum and urinary 
hCG concentrations measured every 2 weeks after 
evacuation. For patients whose hCG concentrations 
spontaneously return to normal within 8 weeks of follow-
up, moni toring is continued for as long as 6 months 
from time of uterine evacuation. When the time taken 
for the hCG concentration to normalise is longer than 
8 weeks, hCG monitoring is continued for a further 
6 months of normal values.24
Clinical records were reviewed and data such as patients’ 
age at registration, date of antecedent pregnancy and 
uterine evacuation, histological subtype, treatment, and 
outcome were noted. All histological changes were 
centrally reviewed as previously described.7,12 Patients with 
non-molar pregnancies, pregnancy within 6 months of 
follow up, and false-positive hCG values were excluded.
All identiﬁ ed patients were reviewed and discussed in 
multidisciplinary meetings every week. Criteria for 
review in clinic 6 months after evacuation were based on 
steady or rising hCG concentrations, symptoms such as 
vaginal bleeding, or hCG concentration of more than 
100 IU/L. Patients who were reviewed in clinic underwent 
a chest radiograph and doppler ultrasound scan of the 
pelvis. Decision to treat with chemotherapy or continue 
surveillance was jointly made by the consultant and 
patient after discussion. No formal randomisation 
process was used.
Panel 1: Charing Cross Hospital indications for 
chemotherapy and FIGO 2000 criteria for diagnosis of 
gestational trophoblastic neoplasia
Charing Cross Hospital indications for chemotherapy in 
gestational trophoblastic disease
• Histological evidence of choriocarcinoma
• Evidence of metastases in brain, liver, or gastrointestinal 
tract, or radiological opacities larger than 2 cm on chest 
radiography
• Pulmonary, vulval, or vaginal metastases unless human 
chorionic gonadotropin concentrations are falling
• Heavy vaginal bleeding, or evidence of gastrointestinal or 
intraperitoneal haemorrhage
• Rising hCG concentrations in two consecutive samples or 
steady concentrations in three consecutive samples after 
evacuation of molar pregnancy
• Serum hCG greater than 20 000 IU/L more than 4 weeks 
after evacuation, because of the risk of uterine perforation
• Raised hCG concentrations 6 months after evacuation, 
even if decreasing
FIGO 2000 criteria for the diagnosis of gestational 
trophoblastic neoplasia after hydatidiform mole
• Consistently high hCG concentrations last for four 
measurements for 3 weeks or longer (days 1, 7, 14, and 21)
• Rise of hCG on three consecutive measurements done 
every week, during 2 weeks or longer (days 1, 7, and 14)
• Histological diagnosis of choriocarcinoma
• hCG concentration high for 6 months or more
hCG=human chorionic gonadotropin.
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hCG concentrations of women who continued under 
surveillance were monitored according to a surveillance 
programme, which entailed measurements of blood and 
urine samples every 2 weeks until normal, and then 
monthly urine samples for a further 6 months.24 The 
women who started chemotherapy sent hCG serum 
samples twice a week until normal, and then once a week 
until 6 weeks after completion of chemotherapy. At this 
point, patients given chemotherapy were reviewed in 
clinic with a repeat doppler ultrasound of the pelvis 
before post-treatment monitoring of hCG in serum and 
urine began. Monitoring was done with decreasing 
frequency until eventually urine samples were necessary 
only every 6 months.25
The primary outcome assessed in patients with 
persistently raised hCG 6 months after evacuation was rate 
of spontaneous hCG normalisation under continued 
surveillance. We also investigated normalisation rates 
in patients who received chemotherapy. Additionally, 
frequency of antecedent complete and partial hyda tidiform 
moles in the two groups, hCG concentrations at registration, 
peak hCG between registration and 6 months, hCG at 
6 months, time to normalisation, and rates of resistance to 
chemotherapy, relapse, and death were also established. 
Because use of oral contraceptives while hCG is still high 
might increase risk of gestational trophoblastic neoplasia,26 
use of these hormones was documented.
Local institutional review board approval was obtained 
for this study. The study was done with anonymised patient 
records and hence informed consent was not needed.
Statistical analyses
Enrolment of 66 patients under surveillance allowed 
exclusion of hCG normalisation rates of less than 75% 
with 100% power, with a two-sided α of 0·05 for a 
95% observed rate of hCG normalisation. Fisher’s exact 
test was used to compare rates of spontaneous hCG 
normalisation and frequency of complete and partial 
hydatidiform moles between chemotherapy and 
surveillance groups. Mann-Whitney U test was used to 
test for diﬀ erences in registration, peak, and 6 month 
hCG concentrations between chemotherapy and 
surveillance groups, and 6 month hCG concentrations 
between responding and non-responding patients who 
received chemotherapy. We assessed the correlation 
between hCG concentration at 6 months and time to 
remission with Spearman’s rank correlation coeﬃ  cient. 
We did statistical analyses with SPSS (version 17·0).
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all data in the study and had ﬁ nal responsibility 
for the decision to submit for publication.
Results
Between Jan 1, 1993, and May 1, 2008, 13 960 patients with 
hydatidiform mole were registered. 974 (7%) required 
chemotherapy, and hCG normalised spontan eously in 
13 960 patients identified
66 continued under surveillance
65 spontaneously
remitted
1 persistently high
concentration
(chronic renal
failure)
10 given chemotherapy
6 full response
2 partial response
2 with no response
12 910 returned to normal
974 given chemotherapy
76 patients with raised hCG 6 months after evacuation of a hydatidiform mole
All alive and well
Figure 1: Management and outcome of patients with high hCG 
concentrations 6 months after evacuation of hydatidiform mole
hCG=human chorionic gonadotropin.
Number of patients 
(n=76)
Median hCG 
concentration at 
6 months (IU/L)
Correlation between hCG 
concentration at 6 months and 
time to remission
<8 months 46 (61%) 12·5 (3–117) r=0·233 ; p=0·049
8–12 months 20 (26%) 17 (6–887) ··
>12 months 7 (9%) 12 (7–798) ··
No return to normal 3 (4%) 7 (6–18) ··
Data are n (%) or median (range). hCG=human chorionic gonadotropin. 
Table: Correlation of hCG concentrations at 6 months with time from initial uterine evacuation to remission
Surveillance
n=66
U=144, p=0·004
Median (IU/L)
Range
13
5–887
157
6–6438
0
Lo
g 1
0 (
hC
G[
IU
/L
])
1
2
3
4
Chemotherapy
n=10
Figure 2: hCG concentrations at 6 months of patients who received 
chemotherapy and those continued under surveillance
hCG=human chorionic gonadotropin.
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See Online for webappendix
12 910 (92%) within 6 months of evacuation. The 
remaining 76 (<1%) patients had persistently high hCG 
values 6 months after evacuation and were included in 
our study (ﬁ gure 1). The median age of the included 
patients was 30 years (range 15–51). Histologically, 
46 (61%) of these patients had complete moles, 25 (33%) 
had partial moles, and ﬁ ve (7%) were unclassiﬁ ed. Median 
plasma hCG concentration at registration was 1343·5 IU/L 
(range 7–1 809 437), peak hCG was 1386 IU/L 
(range 6–1 809 437), hCG at 6 months was 13·5 IU/L 
(range 3–6438), and time to hCG normalisation was 
7·5 months (range 6·1–32·2; webappendix p 1). Overall 
hCG concentration at 6 months was modestly correlated 
with time to hCG normalisation (table).
66 (87%) patients continued under surveillance and did 
not have chemotherapy (ﬁ gure 1). 38 (58%) of these 
individuals had complete hydatidiform mole, 24 (36%) 
had partial mole, and four (6%) were unclassiﬁ ed 
(webappendix p 1). hCG concentrations returned to 
normal in 65 of these patients (98%; 95% CI 95·5–100). 
Values became normal within 8 months of evacuation in 
44 (67%) of patients under surveillance, in the next 
4 months in 15 (23%), and times were longer than 1 year 
for only six (9%). Five of the patients whose times to 
normalisation were longer than 1 year had normal hCG 
concentrations within 18 months of evacuation. The sixth 
patient was oﬀ ered treatment after three consecutive rises 
in hCG concentrations, but she declined chemotherapy 
and was lost to follow-up because she emigrated out of the 
UK. On return, she had a successful pregnancy and her 
hCG subsequently normalised without chemotherapy. 
Therefore, only one patient in the surveillance group 
continued to have slightly raised hCG concentrations 
(range 8–11). This individual was on haemodialysis for 
end-stage renal failure and persistent hCG concentrations 
were therefore attributed to impaired renal clearance. 
Thus, no patients in the surveillance group developed 
gestational trophoblastic neoplasia that needed chemo-
therapy, developed drug resistance, or had a relapse. The 
observed rate of hCG normalisation in the surveillance 
group, suggests that the true hCG normalisation rate is at 
least 85% with 99% conﬁ dence, and is greater than 90% 
with 67% power in the surveillance group. 
Of the ten patients who started on low-risk 
chemotherapy with methotrexate and folinic acid25 
6 months after evacuation of their hydatidiform mole 
(ﬁ gure 1), eight (80%) had complete and two (20%) had 
partial molar pregnancies (webappendix pp 1–2). All 
these women had stage I disease with low FIGO 2000 risk 
factor scores27 of between 1 and 3. Six (60%) patients had 
a complete response to treatment and two (20%) 
individuals showed only a partial response but their hCG 
concentrations returned to normal after cessation of 
chemotherapy (one within 1 week and one in 8 months), 
and so were classiﬁ ed as having a partial response 
(webappendix p 2). The remission rate was 80·0% 
(95% CI 55·2–100).
The treatment of the other two (20%) patients 
given chemotherapy was subsequently stopped. They 
remained well, with slightly increased hCG concen-
trations (range 6–11 IU/L) for 3 and 15 years, and have 
since had successful pregnancies. Patients with partial 
and full responses to chemotherapy had higher hCG 
concen trations at 6 months than did those who had no 
response (median hCG concentrations of 345 IU/L vs 
7 IU/L; p=0·037).
Comparison of patient characteristics in surveillance 
and chemotherapy groups identiﬁ ed no signiﬁ cant 
diﬀ erences in histology (complete or partial mole), age 
at diagnosis, year of diagnosis, hCG concentration at 
regis tration, and peak hCG concentrations (webappendix 
p 1). However, patients under surveillance had lower 
median hCG concentrations 6 months after evacuation 
than did those who received chemotherapy (ﬁ gure 2). 
Importantly, hCG concentrations returned to normal in 
more patients under surveillance than in those on 
chemotherapy (p=0·044), with no signiﬁ cant diﬀ erences 
in time to normalisation between the groups 
(webappendix pp 1–3). No deaths occurred in either the 
surveillance or treatment groups, with an overall median 
follow up of 2·1 years (range 0·6–14·7). No patients 
included took oral contraceptives while their hCG 
concentrations were increased.
Discussion
We have shown that when hCG concentrations are still 
falling 6 months after evacuation of a hydatidiform mole, 
spontaneous normalisation will occur in almost all cases 
without chemotherapy. Moreover, chemotherapy seems 
to be unhelpful in 20–40% of patients given this treatment. 
Therefore, when available, a stringent surveillance 
protocol could be preferable to chemotherapy (panel 2). 
Chemotherapy has several disadvantages. For example, 
although low-risk single-agent chemotherapy regimens 
are generally well tolerated,25,28 they might still be asso-
ciated with some short-term side-eﬀ ects. Additionally, if 
patients are assumed to not be responding to this 
regimen and are then switched to multi-agent chemo-
therapy regimens, toxic eﬀ ects greatly increase in the 
short term,19,29,30 and unlike single-agent treatment also in 
the long term.31 Furthermore, patients in the UK are 
advised not to become pregnant for 12 months after 
chemotherapy. By contrast, individuals under surveil-
lance would have to wait only 6 months after their ﬁ rst 
normal hCG measurement before they could attempt a 
new pregnancy.24 
We do not know if any patients successfully given 
chemotherapy might have spontaneously remitted had 
they been in the surveillance group. So how should a 
decision be made about which patients are suitable for 
observation and which should be given chemotherapy? 
This question is clearly diﬃ  cult to answer. One possibility 
might be the use of a cutoﬀ  hCG concentration for 
requirement of a clinic review with further investigation. 
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Our ﬁ ndings suggest that hCG concentrations can 
spontaneously return to normal in patients with 6 month 
hCG measurements of lower than 887 IU/L, which could 
indicate an upper limit for cutoﬀ  of a surveillance policy. 
Alternatively, on the basis of median hCG value of 
patients who responded to chemotherapy, a cutoﬀ  hCG 
of 345 IU/L could be suggested.
Some patients with a high hCG concentration might 
not need treatment. Two (3%) patients in the surveillance 
group had hCG values higher than 345 IU/L and still 
spontaneously remitted. However, four of six patients 
who responded fully to chemotherapy had hCG concen-
trations greater than 345 IU/L (data not shown). On the 
basis of the few data available, a cutoﬀ  of 345 IU/L on the 
Charing Cross radioimmunoassay for hCG would be 
reasonable until more information is generated.
Other commercial hCG assays can variably detect 
the many hCG fragments or isoforms produced in 
patients with cancer,23 and so the cutoﬀ  value suggested 
might vary depending on the hCG assay used. One 
solution to this diﬃ  culty might be provided through use 
of hyperglycosylated hCG (hCG-H) measurements.32 
Panel 2: Research in context
Systematic review
We searched PubMed for reports from January, 1980, to 
December, 2010, that contained the terms “GTD”, “molar 
pregnancy”, “hydatidiform mole”, “trophoblastic disease”, 
“complete hydatidiform mole”, or “partial hydatidiform 
mole”, and combined these terms with “surveillance”, 
“follow-up”, “monitoring”, “treatment criteria”, “low risk”, or 
“duration from evacuation” to identify any other studies in 
this area of research. Previous reports showed that one 
standard indication for chemotherapy in women who have 
had a molar pregnancy is a persistently high hCG 
concentration 6 months after uterine evacuation of the mole, 
even if it is still falling.6,14,15 We identiﬁ ed no studies that 
speciﬁ cally looked at whether continued hCG surveillance 
6 months after evacuation of molar disease from the uterus is 
clinically acceptable. However, one study showed that 
chemotherapy could help patients with an increased 
hCG concentration beyond 6 months to recover safely.22
Interpretation
As far as we are aware, our study is the ﬁ rst to investigate 
whether continued hCG surveillance is a clinically acceptable 
approach as opposed to chemotherapy. Our ﬁ ndings directly 
challenge the present clinical dogma,6,14,15 and provide data 
showing that continued surveillance for women with high 
but falling hCG concentrations 6 months after uterine 
evacuation of a molar pregnancy is clinically acceptable 
because nearly all patients will spontaneously remit. The 
results are important because they will change international 
practice and spare women unnecessary exposure to 
chemotherapy and its toxic eﬀ ects.
Pre liminary work suggests that an increased ratio of 
hCG-H to total hCG might identify patients with highly 
invasive gestational trophoblastic neoplasia likely to 
beneﬁ t from chemotherapy.32,33 However, this approach 
will not be validated until commercial hCG-H assays are 
more readily available.
So does surveillance of this group of women increase 
the risk that high-risk, drug-resistant disease or placental 
site trophoblastic tumour will develop and potentially 
reduce survival? Encouragingly, no patients died in our 
cohort, or in a group of 28 patients given chemotherapy 
beyond 6 months at another centre (all had low-risk 
disease and were cured).22 Additionally, previous twin 
and singleton studies have shown that delayed evacuation 
does not increase the risk of development of gestational 
trophoblastic neoplasia.20,21
We cannot exclude the possibility that some of these 
hydatidiform moles could have developed into placental 
site trophoblastic tumours,34 which are associated with 
slightly raised hCG concentrations.18 Reassuringly, this 
development has not yet happened in our cohort. Thus, 
our ﬁ ndings suggest that the practice of close surveillance 
could be adopted in the knowledge that these women are 
not being exposed to a signiﬁ cantly increased risk of life-
threatening gestational trophoblastic neoplasia including 
placental site trophoblastic tumour.
This study is limited by retrospective data and small 
patient numbers. A further prospective study in a 
multicentre setting would be useful. However, in the 
absence of these data, we recommend that women with 
persistently high hCG concentrations 6 months after 
evacuation should continue regular hCG monitoring 
rather than begin chemotherapy. Chemotherapy should 
only be considered in patients whose hCG concentrations 
are greater than 345 IU/L, and when radiological evidence 
of disease is present or when hCG levels are consistently 
plateaued or rising.
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